AviMed Pharmaceuticals
Home
Print this pageAdd to Favorite

Overview

 
Repurposing for next generation CNS drugs

AviMed has an advanced drug lead with proven safety and efficacy for treating schizophrenia, and a proprietary technology for generating next generation CNS drugs quickly - based on repurposing. Our initial focus is on schizophrenia, which afflicts 1% of the population. Existing therapeutics are inadequate with significant side effects, so there is an urgent unmet need.


Science and Experience

  • Our team has significant experience in drug design and development, as well as neuropharmacology.
  • Our board has experience building biotech ventures, moving molecules into the clinic, and taking repurposed drugs through clinical trials to NDA approval.
  • Our lead molecule, AV115, shows efficacy for a subset of symptoms that are not treated by existing drugs.
  • AviMed has aggressively filed multiple patents to protect its lead molecule for treating schizophrenia (AV115), as well as a platform technology for rapid repurposing of additional CNS therapeutics.